Omniose
St. Louis, US · 1 known investors
Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.
Founders & leadership
DH
Dr. HardingPrimary Founder
MF
Mario FeldmanFounder, Scientific Founder
VP
Viliam Pavliak
BM
Benjamin Moutier
DS
Dr. Szymanski
DP
Dr. Projan
DC
Dr. Cooke
Investors · 1
In the news
- Omniose Receives $3.6M Grant from NIHfinsmes.com · 2022
- Publications | Omnioseomniose.com · 2022
- Blog | Omnioseomniose.com · 2018